Adamis pharmaceuticals corp (ADMP)
Income statement / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Mar'14Mar'13Mar'12Mar'11
REVENUE, net

22,113

15,086

13,073

-

-

-

-

-

0

0

REVENUE, net

-

-

-

6,473

-

-

-

-

-

-

COST OF GOODS SOLD

-

-

-

4,853

-

-

-

-

-

-

COST OF GOODS SOLD

15,478

9,797

7,419

-

-

-

-

-

-

-

Gross Profit

6,635

5,288

5,653

1,620

-

-

-

-

-

-

SELLING, GENERAL AND ADMINISTRATIVE EXPENSES

25,287

25,948

22,819

17,127

9,007

5,791

3,389

2,008

2,649

3,365

RESEARCH AND DEVELOPMENT

10,375

18,793

7,526

9,697

4,843

3,924

1,006

1,209

2,165

2,875

IMPAIRMENT EXPENSE

322

10

-

-

-

-

-

-

-

-

LOSS ON IMPAIRMENT OF FIXED ASSETS

-

-

96

-

-

-

-

-

-

-

Loss from Operations

-29,350

-39,463

-24,789

-25,204

-13,850

-9,716

-4,395

-3,217

-4,815

-6,241

OTHER INCOME (EXPENSE)
Interest Expense

123

157

231

214

-

371

8,626

2,333

35

744

Interest Income

175

245

102

9

-

-

-

-

-

-

Inducement Expense for Exercise of Warrants

-

-

960

-

-

-

-

-

-

-

Gain on Extinguishment of Debt

-

-

-

-

-

-

198

-

-

-

Change in Fair Value of Warrant Liability

-

-

-

-1,049

-433

926

-762

-

-

-

Change in Fair Value of Warrant Derivative Liabilities

-

-

-

348

-155

46

-

-

-

-

Gain on Sale of Asset

-

-

-

-

-

-

-

-

5

5

Change in Fair Value of Derivative Liabilities

-

-

-

-

-

-

919

-122

0

-

Change in Fair Value of Conversion Feature Liability

-

-

-

-

-

-

2,985

-1,390

-

-

Change in Fair Value of Conversion Feature Liability

-

-

-

-

-

-

-

-

0

-

Total Other Income (Expense), net

52

87

-1,089

1,192

278

-1,052

-3,760

-3,847

-30

-738

(Loss) Before Income Taxes

-29,298

-39,376

-25,878

-24,012

-

-

-

-

-

-

Income Tax (Expense) Benefit

8

-369

-339

-4,574

-

-

-

-

-

-

(Loss) from Continuing Operations

-

-

-

-

-

-

-

-7,064

-4,845

-6,979

Write-down of Discontinued Operations Receivable

-

-

-

-

-

-

-

-130

-

-

Write-down of Discontinued Operations Receivable

-

-

-

-

-

-

-

-

-70

-

Write-down of Discontinued Operations Receivable

-

-

-

-

-

-

-

-

-

0

(Loss) from Discontinued Operations

-

-

-

-

-

-

-

-130

-70

0

Net (Loss)

-29,306

-39,006

-25,538

-19,437

-13,571

-10,768

-8,155

-7,194

-4,915

-6,979

Deemed Dividend on Preferred Stock

-

-

-

1,374

-

-

-

-

-

-

Net (Loss) Applicable to Common Stock

-

-

-

-20,811

-

-

-

-

-

-

Basic and Diluted (Loss) Per Share
Basic and Diluted (Loss) Per Share from Continuing Operations

-

-

-

-

-

-

-

-

-0.06

-0.11

Basic and Diluted (Loss) Per Share from Discontinued Operations

-

-

-

-

-

-

-

-

0.00

0.00

Basic and Diluted (Loss) Per Share (in dollars per share)

-0.55

-1.00

-0.90

-1.19

-

-

-

-

-0.06

-0.11

Basic and Diluted Weighted Average Shares Outstanding (in shares)

53,263

39,085

28,349

17,500

-

-

-

-

89,477

63,786

Loss from Continuing Operations-basic

-

-

-

-

-

-

-

-1.21

-

-

Loss from Discontinued Operations-basic

-

-

-

-

-

-

-

-0.02

-

-

Basic (Loss) Per Share

-

-

-

-

-1.02

-1.03

-1.11

-1.23

-

-

Basic Weighted Average Shares Outstanding

-

-

-

-

13,275

10,491

7,346

5,858

-

-

Loss from Continuing Operations-diluted

-

-

-

-

-

-

-

-1.21

-

-

Loss from Discontinued Operations-diluted

-

-

-

-

-

-

-

-0.02

-

-

Diluted (Loss) Per Share

-

-

-

-

-1.03

-1.03

-1.22

-1.23

-

-

Diluted Weighted Average Shares Outstanding

-

-

-

-

13,436

10,491

7,493

5,858

-

-